招银国际每日投资策略-20260205

Core Insights - Pfizer reported strong Q4 2025 earnings with revenue of $17.6 billion, aligning closely with previous expectations of $18.1 billion, and adjusted net income of $3.8 billion, exceeding the prior forecast of $3.3 billion [2] - Total revenue for 2025 is projected at $62.6 billion, a 2% year-over-year decline, but operational revenue excluding COVID-19 products grew by 6%, indicating robust underlying business momentum [2] - The management reaffirmed guidance for 2026, expecting revenue between $59.5 billion and $62.5 billion, with adjusted EPS ranging from $2.80 to $3.00, highlighting a year rich in catalysts [2] Company Analysis - Pfizer's pipeline includes significant catalysts such as long-acting GLP-1 and Amylin projects, with key data readouts expected in 2026 [2] - The VESPER-3 study demonstrated a 12.3% weight loss effect at the 28-week mark for the mid-dose group of PF'3944, with predictions suggesting a 15.8% weight loss for the high-dose group [6] - The company plans to initiate a Phase 3 study for PF'3944 later this year, with further updates on its obesity product portfolio expected [6][7] Market Performance - The Hang Seng Index closed at 26,847, reflecting a slight increase of 0.05% for the day and a year-to-date gain of 4.75% [2] - The U.S. stock market saw declines, particularly in technology and consumer discretionary sectors, while energy and materials sectors showed strength [4] - Notable movements included a 17% drop in AMD shares following weak guidance, impacting the semiconductor sector [4]